150 / 172
150
infliximab plus methotrexate in patients with early rheumatoid
arthritis. Ann Rheum Dis 2009;68:1153-8.
58. van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF,
Cöster L, Waltbrand E, et al. Addition of infliximab compared
with addition of sulfasalazine and hydroxychloroquine to
methotrexate in patients with early rheumatoid arthritis
(Swefot trial): 1-year results of a randomised trial. Lancet
2009;374:459-66.
59. Genovese MC, Bathon JM, Martin RW, Fleischmann RM,
Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in
patients with early rheumatoid arthritis: two-year
radiographic and clinical outcomes. Arthritis Rheum
2002;46:1443-50.
60. Keystone E, Genovese MC, Klareskog L, Hsia EC, Hall S,
Miranda PC, et al. Golimumab in patients with active
rheumatoid arthritis despite methotrexate therapy: 52-week
results of the GO-FORWARD study. Ann Rheum Dis
2010;69:1129-35.
61. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et
al. Risk of serious bacterial infections among rheumatoid
arthritis patients exposed to tumor necrosis factor alpha
antagonists. Arthritis Rheum 2007;56:1125-33.
62. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL;
British Society for Rheumatology Biologics Register Control
Centre Consortium, et al. Serious infection following anti-
tumor necrosis factor alpha therapy in patients with
rheumatoid arthritis: lessons from interpreting data from
observational studies. Arthritis Rheum 2007;56:2896-904.
63. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen
FH, Enevold C, van Riel PL, et al. Formation of antibodies
against infliximab and adalimumab strongly correlates with
functional drug levels and clinical responses in rheumatoid
arthritis. Ann Rheum Dis 2009;68:1739-45.